Biennial FOB test screening program for bowel cancer cost-effective

January 01, 0001

Biennial FOB test screening program for bowel cancer cost-effective

The aim of this study was to examine the costs and cost-effectiveness of full implementation of biennial bowel cancer screening for Australian residents aged 50-74 years. Identification of existing economic models from 1993 to 2010 through searches of PubMed and economic analysis databases, and by seeking expert advice; and additional modelling to determine the costs and cost-effectiveness of full implementation of biennial faecal occult blood (FOB) test screening for the five million adults in Australia aged 50-74 years.

The researchers identified six relevant economic analyses, all of which found colorectal cancer (CRC) screening to be very cost-effective, with costs per LYG under $55,000 per year in 2010 Australian dollars. Based on their additional modelling, they conservatively estimate that full implementation of biennial screening for people aged 50-74 years would have gross costs of $150 million, reduce CRC mortality by 15%-25%, prevent 300-500 deaths from bowel cancer, and save 3600-6000 life- years annually, for an undiscounted cost per LYG of $25,000-$41,667, compared with no screening, and not taking cost savings as a result of treatment into consideration. The additional expenditure required, after accounting for reductions in CRC incidence, savings in CRC treatment costs, and existing ad-hoc colonoscopy use, is likely to be less than $50 million annually.

The researchers concluded: "Full implementation of biennial faecal occult blood test screening in Australia can reduce bowel cancer mortality, and is an efficient use of health resources that would require modest additional government investment."

An important cost-effectiveness analysis.

For the full abstract, click here.

MJA 194(4):180-185, 21 February 2011 © The Medical Journal of Australia 2011
Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. Michael P Pignone, Kathy L Flitcroft, Kirsten Howard et al. Correspondence to Michael Pignone: [email protected]

Category: D. Digestive. Keywords: costs, cost-effectiveness , biennial, faecal, occult blood, test, screening, program, bowel cancer, economic analyses, journal watch.
Synopsis edited by Dr Stephen Wilkinson, Melbourne, Australia. Posted on Global Family Doctor 11 March 2010

Pearls are an independent product of the Cochrane primary care group and are meant for educational use and not to guide clinical care.